SLS SELLAS Life Sciences Group, Inc. - Common Stock
حول SELLAS Life Sciences Group, Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..
اقرأ المزيد
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigation their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
SLS لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
SLS مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
SLS توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
- شراء قوي 1 16,7%
- شراء 4 66,7%
- احتفاظ 1 16,7%
- بيع 0 0,0%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
2 محللين · 2026-08-14سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 31 مارس، 2026 | $-0.05 | $-0.04 | -0.01% |
| 31 ديسمبر، 2025 | $-0.05 | $-0.07 | 0.02% |
| 30 سبتمبر، 2025 | $-0.06 | $-0.07 | 0.01% |
| 30 يونيو، 2025 | $-0.07 | $-0.08 | 0.01% |
| 31 مارس، 2025 | $-0.07 | $-0.11 | 0.04% |
| 31 ديسمبر، 2024 | $-0.08 | $-0.11 | 0.03% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 15
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
الميزانية العمومية 22
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
التدفق النقدي 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
الربحية 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
السيولة والملاءة 4
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
الكفاءة 1
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
معدلات النمو 1
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
قائمة الدخل 12
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
الميزانية العمومية 15
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
التدفق النقدي 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
الربحية 5
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
السيولة والملاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
الكفاءة 1
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
التقييم (آخر 12 شهرًا) 9
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $1M | · | $1M | |
| Net Income TTM | $-31M | $-28M | · | $-26M | $-27M | $-30M | · | $-33M | $-35M | $-39M | · | $-36M | $-35M | $-43M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -64.2 | -16.9 | · | -5.4 | -5.9 | -2.1 | · | -1.6 | -1.2 | -0.8 | · | -1.1 | -1.0 | -0.6 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 40.5 | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.6% | -5.9% | · | -18.6% | -16.9% | -47.2% | · | -61.6% | -82.3% | -130.7% | · | -88.4% | -97.5% | -158.7% | · | -111.4% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | — | — | $0 | $1M | $8M |
| هامش الربح التشغيلي % | — | — | — | -4195.0% | -332.8% |
| صافي الدخل | $-27M | $-31M | $-37M | $-41M | $-21M |
| EPS المخفف | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| النسبة الحالية | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| النسبة السريعة | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 231 مقدمي إقرار · $1.2B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 87 (+24 مقابل الربع السابق) | 19 (+4 مقابل الربع السابق) | 70 (+12 مقابل الربع السابق) | 38 (+15 مقابل الربع السابق) | +39.9M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| STATE STREET CORP | $191829196 | 12996558 | 15,97% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $121417310 | 8226105 | 10,11% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105640272 | 7157200 | 8,79% | عقد خيار الشراء |
| Anson Funds Management LP | $66420000 | 4500000 | 5,53% | الأسهم |
| CITADEL ADVISORS LLC | $64157292 | 4346700 | 5,34% | عقد خيار الشراء |
| GEODE CAPITAL MANAGEMENT, LLC | $61905400 | 4193009 | 5,15% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61832592 | 4189200 | 5,15% | عقد خيار البيع |
| CITADEL ADVISORS LLC | $33333984 | 2258400 | 2,77% | عقد خيار البيع |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31897821 | 2161099 | 2,66% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30266812 | 2050597 | 2,52% | الأسهم |
| JONES FINANCIAL COMPANIES LLLP | $28553511 | 2304561 | 2,38% | الأسهم |
| VANGUARD GROUP INC | $27868421 | 7392154 | 2,32% | الأسهم |
| Anson Funds Management LP | $27245484 | 1845900 | 2,27% | عقد خيار البيع |
| PERCEPTIVE ADVISORS LLC | $22140000 | 1500000 | 1,84% | عقد خيار البيع |
| VANGUARD FIDUCIARY TRUST CO | $19707050 | 1335166 | 1,64% | الأسهم |
| Sio Capital Management, LLC | $18165132 | 1230700 | 1,51% | عقد خيار البيع |
| BNP PARIBAS FINANCIAL MARKETS | $15823045 | 1072022 | 1,32% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $13372560 | 906000 | 1,11% | عقد خيار البيع |
| BARCLAYS PLC | $11831616 | 801600 | 0,98% | عقد خيار البيع |
| Anson Funds Management LP | $11808000 | 800000 | 0,98% | عقد خيار الشراء |
| BNP PARIBAS FINANCIAL MARKETS | $11734200 | 7950 | 0,98% | عقد خيار البيع |
| JANE STREET GROUP, LLC | $11058192 | 749200 | 0,92% | عقد خيار الشراء |
| MORGAN STANLEY | $9922380 | 672248 | 0,83% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $9150359 | 619943 | 0,76% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8339518 | 565008 | 0,69% | الأسهم |
| JANE STREET GROUP, LLC | $7462700 | 505603 | 0,62% | الأسهم |
| Balyasny Asset Management L.P. | $7380000 | 500000 | 0,61% | عقد خيار البيع |
| LMR Partners LLP | $6642000 | 450000 | 0,55% | عقد خيار البيع |
| NOMURA HOLDINGS INC | $6273000 | 425000 | 0,52% | عقد خيار الشراء |
| DIADEMA PARTNERS LP | $5904000 | 400000 | 0,49% | عقد خيار الشراء |
| Swiss National Bank | $5319504 | 360400 | 0,44% | الأسهم |
| XTX Topco Ltd | $5300168 | 359090 | 0,44% | الأسهم |
| Ikarian Capital, LLC | $5235372 | 354700 | 0,44% | عقد خيار البيع |
| CITIGROUP INC | $4659717 | 315699 | 0,39% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $4580973 | 310364 | 0,38% | الأسهم |
| DAGCO, INC. | $4351740 | 1028780 | 0,36% | الأسهم |
| Everhart Financial Group, Inc. | $4251146 | 288018 | 0,35% | الأسهم |
| Rafferty Asset Management, LLC | $3540806 | 239892 | 0,29% | الأسهم |
| RHUMBLINE ADVISERS | $3400726 | 230402 | 0,28% | الأسهم |
| Walleye Capital LLC | $3377088 | 228800 | 0,28% | عقد خيار البيع |
| GOLDMAN SACHS GROUP INC | $3125991 | 211788 | 0,26% | الأسهم |
| TUDOR INVESTMENT CORP ET AL | $3087792 | 209200 | 0,26% | عقد خيار البيع |
| WELLINGTON MANAGEMENT GROUP LLP | $2992738 | 202760 | 0,25% | الأسهم |
| BOOTHBAY FUND MANAGEMENT, LLC | $2982996 | 202100 | 0,25% | عقد خيار البيع |
| Jefferies Financial Group Inc. | $2958775 | 200459 | 0,25% | الأسهم |
| Jefferies Financial Group Inc. | $2953476 | 200100 | 0,25% | عقد خيار البيع |
| Mariner, LLC | $2925609 | 198212 | 0,24% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $2895912 | 196200 | 0,24% | عقد خيار الشراء |
| Bank of New York Mellon Corp | $2801212 | 189784 | 0,23% | الأسهم |
| ALPS ADVISORS INC | $2776459 | 188107 | 0,23% | الأسهم |
| JANE STREET GROUP, LLC | $2405880 | 163000 | 0,20% | عقد خيار البيع |
| LPL Financial LLC | $2297586 | 155663 | 0,19% | الأسهم |
| SIMPLEX TRADING, LLC | $2274501 | 154099 | 0,19% | الأسهم |
| BlackRock, Inc. | $2222708 | 150590 | 0,19% | الأسهم |
| WELLS FARGO & COMPANY/MN | $2208775 | 149646 | 0,18% | الأسهم |
| Vontobel Holding Ltd. | $2166207 | 146762 | 0,18% | الأسهم |
| TUDOR INVESTMENT CORP ET AL | $2069352 | 140200 | 0,17% | عقد خيار الشراء |
| Vanguard Global Advisers, LLC | $1918874 | 130005 | 0,16% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $1859598 | 125989 | 0,15% | الأسهم |
| Caption Management, LLC | $1845000 | 125000 | 0,15% | عقد خيار البيع |
| PROFUND ADVISORS LLC | $1780159 | 120607 | 0,15% | الأسهم |
| MetLife Investment Management, LLC | $1624810 | 110082 | 0,14% | الأسهم |
| Daiwa Securities Group Inc. | $1589652 | 107700 | 0,13% | عقد خيار البيع |
| Daiwa Securities Group Inc. | $1512900 | 102500 | 0,13% | الأسهم |
| DIADEMA PARTNERS LP | $1476000 | 100000 | 0,12% | عقد خيار البيع |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $1467144 | 99400 | 0,12% | الأسهم |
| STATE OF WISCONSIN INVESTMENT BOARD | $1405300 | 95210 | 0,12% | الأسهم |
| Harvest Investment Services, LLC | $1394554 | 94482 | 0,12% | الأسهم |
| ORBIMED ADVISORS LLC | $1365300 | 92500 | 0,11% | عقد خيار البيع |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $1229582 | 83305 | 0,10% | الأسهم |
| Invesco Ltd. | $1104816 | 74852 | 0,09% | الأسهم |
| Gotham Asset Management, LLC | $1097317 | 74344 | 0,09% | الأسهم |
| FULCRUM WEALTH ADVISORS, LLC | $1081214 | 73253 | 0,09% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $998534 | 236060 | 0,08% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $978588 | 66300 | 0,08% | الأسهم |
| Verition Fund Management LLC | $916596 | 62100 | 0,08% | عقد خيار البيع |
| OSAIC HOLDINGS, INC. | $889776 | 60284 | 0,07% | الأسهم |
| FIFTH THIRD BANCORP | $888404 | 60190 | 0,07% | الأسهم |
| State of New Jersey Common Pension Fund D | $857069 | 58067 | 0,07% | الأسهم |
| Verition Fund Management LLC | $832464 | 56400 | 0,07% | عقد خيار الشراء |
| Police & Firemen's Retirement System of New Jersey | $821630 | 55666 | 0,07% | الأسهم |
| ARIZONA STATE RETIREMENT SYSTEM | $731388 | 49552 | 0,06% | الأسهم |
| Caption Management, LLC | $728745 | 49373 | 0,06% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $722310 | 48937 | 0,06% | الأسهم |
| Russell Investments Group, Ltd. | $704494 | 47730 | 0,06% | الأسهم |
| SIG BROKERAGE, LP | $689292 | 46700 | 0,06% | عقد خيار الشراء |
| Vanguard Investments Australia, Ltd. | $684643 | 46385 | 0,06% | الأسهم |
| COMMONWEALTH EQUITY SERVICES, LLC | $665481 | 45087 | 0,06% | الأسهم |
| INSTRUMENTAL WEALTH, LLC | $662931 | 44914 | 0,06% | الأسهم |
| Persistent Asset Partners Ltd | $655647 | 758 | 0,05% | عقد خيار الشراء |
| Virtus Investment Advisers, LLC | $616791 | 41788 | 0,05% | الأسهم |
| Accurate Wealth Management, LLC | $614707 | 47462 | 0,05% | الأسهم |
| AXXCESS WEALTH MANAGEMENT, LLC | $610665 | 41373 | 0,05% | الأسهم |
| KLP KAPITALFORVALTNING AS | $600732 | 40700 | 0,05% | الأسهم |
| SJS Investment Consulting Inc. | $590400 | 40000 | 0,05% | الأسهم |
| Wealthfront Advisers LLC | $587773 | 39822 | 0,05% | الأسهم |
| Quantinno Capital Management LP | $546651 | 37036 | 0,05% | الأسهم |
| Visionary Horizons, LLC | $531360 | 36000 | 0,04% | الأسهم |
| Kestra Advisory Services, LLC | $516305 | 34980 | 0,04% | الأسهم |
| NORTHSTAR ASSET MANAGEMENT Co | $509400 | 45000 | 0,04% | الأسهم |
المطلعون على الشركة 42 من المطلعين · مسؤولون 17 · مديرون 9
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 16 يونيو، 2026 A | 1759183 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 15 مارس، 2011 A | 92994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 7 يناير، 2026 A | 554327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 20 إبريل، 2018 A | — | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 13 إبريل، 2011 A | 379294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 15 يناير، 2009 A | — | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 7 يناير، 2026 A | 557805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 22 يناير، 2024 A | 40918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 22 يناير، 2024 A | 117225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 14 مارس، 2019 A | — | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 13 مارس، 2018 A | — | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 15 مارس، 2011 A | 14065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 15 مارس، 2011 A | 41083 | 0 | 0 | $0 |
| Anastasia Khvorova | Chief Science Officer | 15 مارس، 2011 A | 60559 | 0 | 0 | $0 |
| Pamela Pavco | VP of Pharmaceutical Devlpmt | 15 مارس، 2011 A | 44940 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 15 إبريل، 2010 A | 5750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 31 مارس، 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | مدير | 7 يناير، 2026 A | 154400 | 1 | 0 | $100806 |
| John Varian | مدير | 7 يناير، 2026 A | 72900 | 0 | 0 | $0 |
| Jane Wasman | مدير | 7 يناير، 2026 A | 92900 | 0 | 0 | $0 |
| David A Scheinberg | مدير | 7 يناير، 2026 A | 73082 | 0 | 0 | $0 |
| Robert L Van Nostrand | مدير | 7 يناير، 2026 A | 82900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | مدير | 14 مارس، 2019 A | — | 0 | 0 | $0 |
| Fabio Lopez | مدير | 12 يونيو، 2018 A | — | 0 | 0 | $0 |
| Irving M. Einhorn | — | 10 أكتوبر، 2017 A | 34690 | 0 | 0 | $0 |
| William Ashton | — | 10 أكتوبر، 2017 A | 38154 | 0 | 0 | $0 |
| Richard Chin | — | 10 أكتوبر، 2017 A | 31339 | 0 | 0 | $0 |
| Rudolph Nisi | — | 10 أكتوبر، 2017 A | 42918 | 0 | 0 | $0 |
| Sanford Hillsberg | — | 10 أكتوبر، 2017 A | 56950 | 0 | 0 | $0 |
| Mary Ann Gray | — | 10 أكتوبر، 2017 A | 39167 | 0 | 0 | $0 |
| Stephen S Galliker | — | 10 أكتوبر، 2017 A | 36039 | 0 | 0 | $0 |
| Thomas J Knapp | — | 6 فبراير، 2017 A | — | 0 | 0 | $0 |
| Bijan Nejadnik | — | 17 يناير، 2017 A | — | 0 | 0 | $0 |
| Ryan Dunlap | — | 1 يونيو، 2016 M | 18702 | 0 | 0 | $0 |
| Mark W. Schwartz | — | 18 ديسمبر، 2015 A | 415972 | 0 | 0 | $0 |
| Steven A Kriegsman | — | 19 يونيو، 2015 A | 5000 | 0 | 0 | $0 |
| Margaret Kivinski | — | 16 يناير، 2015 A | — | 0 | 0 | $0 |
| Brian L Hamilton | — | 30 يونيو، 2014 J | 2461 | 0 | 0 | $0 |
| Mark J Ahn | — | 30 يونيو، 2014 A | 116225 | 0 | 0 | $0 |
| Rosemary Mazanet | — | 29 يناير، 2013 A | — | 0 | 0 | $0 |
| CYTRX CORP | — | 29 ديسمبر، 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | — | 15 يناير، 2009 A | — | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 2 حيازتان
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 إيداعات | 10 أكتوبر، 2018 | — | إيداع أولي | — | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 8 يناير، 2018 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 29 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,77% | 288499 SH | 8 أغسطس، 2026 | يومي |
| IWC · iShares Trust | 0,50% | 640415 SH | 8 أغسطس، 2026 | يومي |
| LABU · Direxion Shares ETF Trust | 0,26% | 268465 NS | 30 إبريل، 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,23% | 316525 SH | 8 أغسطس، 2026 | يومي |
| ICOP · iShares Trust | 0,22% | 126361 SH | 8 أغسطس، 2026 | يومي |
| CANC · Tema ETF Trust | 0,22% | 40702 NS | 31 مايو، 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,16% | 202339 SH | 8 أغسطس، 2026 | يومي |
| IWO · iShares Trust | 0,14% | 1712069 SH | 8 أغسطس، 2026 | يومي |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,08% | 1086285 SH | 8 أغسطس، 2026 | يومي |
| IWM · iShares Trust | 0,07% | 4828431 SH | 8 أغسطس، 2026 | يومي |
| ISCG · iShares Trust | 0,07% | 57511 SH | 8 أغسطس، 2026 | يومي |
| GSSC · Goldman Sachs ETF Trust | 0,05% | 51293 NS | 31 مايو، 2026 | N-PORT |
| PICK · iShares, Inc. | 0,04% | 122564 SH | 8 أغسطس، 2026 | يومي |
| ITWO · ProShares Trust | 0,04% | 8088 NS | 31 مايو، 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,04% | 540244 SH | 8 أغسطس، 2026 | يومي |
| ISCF · iShares Trust | 0,04% | 30200 SH | 8 أغسطس، 2026 | يومي |
| ISCB · iShares Trust | 0,03% | 8283 SH | 8 أغسطس، 2026 | يومي |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2134285 SH | 8 أغسطس، 2026 | يومي |
| WSML · iShares Trust | 0,03% | 16889 SH | 8 أغسطس، 2026 | يومي |
| RSSL · Global X Funds | 0,03% | 74459 NS | 30 إبريل، 2026 | N-PORT |
| UWM · ProShares Trust | 0,02% | 6326 NS | 31 مايو، 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 6397 NS | 31 مايو، 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 161 NS | 31 مايو، 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 64480 NS | 31 مايو، 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 3554 NS | 31 مايو، 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 273812 SH | 8 أغسطس، 2026 | يومي |
| IWV · iShares Trust | 0,00% | 43929 SH | 8 أغسطس، 2026 | يومي |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5908560 SH | 8 أغسطس، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 15706 SH | 8 أغسطس، 2026 | يومي |